×
It looks like you're using an obsolete version of internet explorer. Internet explorer is no longer supported by Microsoft since the end of 2015. We invite you to use a newer browser such as Firefox, Google Chrome or Microsoft Edge.
My Player placeholder

Become an Incathlab member and receive full access to its content!

You must be an Incathlab member to access videos without any restrictions. Register for free in one minute and access all services provided by Incathlab.You will also be able to log into Incathlab from your Facebook or twitter account by clicking on login on the top-right corner of Incathlab website.

Registration Login


Case summary

-55-year-old male
-Hypertension, dyslipidemia
-Oct 2015: NSTEMI: long lesion in the context of myocardial bridging on mid LAD; FFR 0.75 à PCI on middle LAD with Biomatrix 3.5x11 mm, Stentys Xposition S 3.0-3.5x27 and 2.5-3.0x22 mm; postdilatation 3.0 NC 20 atm
-Dec 2016: In-stent occlusion (Stentys); unsuccessful PCI
-Possible Stentys fracture in mid LAD; ipsilateral epicardial collateral from CX
-SYNTAX score: 13.5
-J-CTO score: 2 (long occlusion; redo procedure)

Strategy

ACCESSES:

-Femoral 7F; XB 3.5 catheter, long sheath

APPROACHES:

-Antegrade true-to-true
-Corsair + Fielder FC
-OCT
-Scoring balloon; NC balloon
-Stenting
-Post dilatation with NC balloon
-OCT

Protocol: OptiRAY (Ioversol)

-Concentration: 350 mgl/mL
-Flow rate: 4mL/s
-Volume per injection: 14 ml
-Volume: 340 mL

 

Shooting date : 2017-01-26
Last update : 2021-06-09

OptiRAY® / Guerbet

Optiray® contrast agent is lower osmolar, lower viscosity and nonionic.

Ballon Scarifiant Actif Angiosculpt X / Philips

Cathéter à ballonnet d’abrasion pour Angioplastie coronaire transluminale percutanée (PTCA) enrobé d’un médicament

Suggestions

Wednesday, May 22nd 2024 from 03pm to 04pm (GMT+2)
Honolulu : Wednesday, May 22nd 2024 from 03am to 04am (GMT+2)
San Francisco : Wednesday, May 22nd 2024 from 06am to 07am (GMT+2)
New York : Wednesday, May 22nd 2024 from 09am to 10am (GMT+2)
Buenos Aires : Wednesday, May 22nd 2024 from 10am to 11am (GMT+2)
Reykjavik : Wednesday, May 22nd 2024 from 01pm to 02pm (GMT+2)
London / Dublin : Wednesday, May 22nd 2024 from 02pm to 03pm (GMT+2)
Paris / Berlin : Wednesday, May 22nd 2024 from 03pm to 04pm (GMT+2)
Istanbul : Wednesday, May 22nd 2024 from 04pm to 05pm (GMT+2)
Moscou / Dubaï : Wednesday, May 22nd 2024 from 05pm to 06pm (GMT+2)
Bangkok : Wednesday, May 22nd 2024 from 08pm to 09pm (GMT+2)
Shanghai : Wednesday, May 22nd 2024 from 09pm to 10pm (GMT+2)
Tokyo : Wednesday, May 22nd 2024 from 10pm to 11pm (GMT+2)
Sydney : Thursday, May 23rd 2024 from 12am to 01am (GMT+2)
Wellington : Thursday, May 23rd 2024 from 02am to 03am (GMT+2)

DanGER shock trial results and the significance to reduce adverse events

Share
Saturday, November 8th 2025 from 01:30pm to 02:15pm (GMT+1)
Honolulu : Saturday, November 8th 2025 from 01:30am to 02:15am (GMT+1)
San Francisco : Saturday, November 8th 2025 from 03:30am to 04:15am (GMT+1)
New York : Saturday, November 8th 2025 from 06:30am to 07:15am (GMT+1)
Buenos Aires : Saturday, November 8th 2025 from 08:30am to 09:15am (GMT+1)
London / Dublin : Saturday, November 8th 2025 from 11:30am to 12:15pm (GMT+1)
Paris / Berlin : Saturday, November 8th 2025 from 12:30pm to 01:15pm (GMT+1)
Istanbul : Saturday, November 8th 2025 from 01:30pm to 02:15pm (GMT+1)
Moscou / Dubaï : Saturday, November 8th 2025 from 03:30pm to 04:15pm (GMT+1)
Bangkok : Saturday, November 8th 2025 from 06:30pm to 07:15pm (GMT+1)
Shanghai : Saturday, November 8th 2025 from 07:30pm to 08:15pm (GMT+1)
Tokyo : Saturday, November 8th 2025 from 08:30pm to 09:15pm (GMT+1)
Sydney : Saturday, November 8th 2025 from 09:30pm to 10:15pm (GMT+1)
Wellington : Saturday, November 8th 2025 from 11:30pm to 12:15am (GMT+1)

SELUTION DeNovo 1-year data – New data = New perspectives?

What do the SELUTION DeNovo 1-year results mean for clinical practice in Germany?

Share
Scroll Up